First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Blood

Volumn 131, Issue 23, 2018, Pages 2515-2527

  Romee, Rizwan ^a   Cooley, Sarah ^b   Berrien Elliott, Melissa M ^a   Westervelt, Peter ^a   Verneris, Michael R ^b   Wagner, John E ^b   Weisdorf, Daniel J ^b   Blazar, Bruce R ^b   Ustun, Celalettin ^b   DeFor, Todd E ^b   Vivek, Sithara ^c   Peck, Lindsey ^a   DiPersio, John F ^a   Cashen, Amanda F ^a   Kyllo, Rachel ^d   Musiek, Amy ^a,d   Schaffer, András ^d   Anadkat, Milan J ^a,d   Rosman, Ilana ^d   Miller, Daniel ^e   Egan, Jack O ^f   Jeng, Emily K ^f   Rock, Amy ^f   Wong, Hing C ^f   Fehniger, Todd A ^a   Miller, Jeffrey S ^b   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Blood and Marrow Transplant Program   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Division of Dermatology   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f ALTOR BIOSCIENCE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALT 803; ANTINEOPLASTIC AGENT; CYTOKINE RECEPTOR AGONIST; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; UNCLASSIFIED DRUG; ALT-803; PROTEIN;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLERGIC RHINITIS; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTEREMIA; BLEEDING; BONE MARROW; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CHILL; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; CYTOPENIA; DIFFUSE LARGE B CELL LYMPHOMA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ELECTROLYTE DISTURBANCE; ERYTHEMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOTENSION; HYPOXIA; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE RASH; INJECTION SITE REACTION; KIDNEY DISEASE; LIVER FUNCTION TEST; LYMPHOCYTE; MALE; MAXIMUM CONCENTRATION; MOUTH DISEASE; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PEMPHIGUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RELAPSE; REMISSION; SIDE EFFECT; STEM CELL EXPANSION; SYSTEMIC THERAPY; AGONISTS; CLINICAL TRIAL; DRUG EFFECT; DRUG THERAPY; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MIDDLE AGED; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-15; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTEINS; YOUNG ADULT;

EID: 85048273123     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-12-823757     Document Type: Article

References (36)

1. Ustun C, Wiseman AC, Defor TE, et al. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplant. 2013;48(11):1415-1420.
2. de Lima M, Porter DL, Battiwalla M, et al. Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant. 2014;20(1):4-13.
3. Kolb HJ, Schattenberg A, Goldman JM, et al; European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041-2050.
4. Nikiforow S, Kim HT, Daley H, et al. A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica. 2016;101(10):1251-1259.
5. Posthuma EF, Marijt EWA, Barge RM, et al. a-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Biol Blood Marrow Transplant. 2004;10(3):204-212.
6. Davids MS, Kim HT, Bachireddy P, et al; Leukemia and Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375(2): 143-153.
7. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-469.
8. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562): 2097-2100.
9. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113(3): 726-732.
10. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411-2419.
11. Venstrom JM, Pittari G, Gooley TA, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med. 2012;367(9):805-816.
12. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8): 3051-3057.
13. Bachanova V, Cooley S, Defor TE, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014;123(25):3855-3863.
14. Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016; 8(357):357ra123.
15. Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo). 2014;2014:205796.
16. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6(8):595-601.
17. Rubinstein MP, Kovar M, Purton JF, et al. Converting IL-15 to a superagonist by binding to soluble IL-15Ralpha. Proc Natl Acad Sci USA. 2006;103(24):9166-9171.
18. Xu W, Jones M, Liu B, et al. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor aSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 2013;73(10): 3075-3086.
19. Rosario M, Liu B, Kong L, et al. The IL-15based ALT-803 complex enhances Fc RIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas. Clin Cancer Res. 2016;22(3):596-608.
20. Conlon KC, Lugli E, Welles HC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015; 33(1):74-82.
21. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
22. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-586.
23. Durie BGM, Harousseau J-L, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9): 1467-1473.
24. Cichocki F, Cooley S, Davis Z, et al. CD56dimCD571NKG2C1 NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia. 2016; 30(2):456-463.
25. Waldmann TA. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res. 2015;3(3):219-227.
26. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633-640.
27. Wagner JA, Rosario M, Romee R, et al. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest. 2017;127(11):4042-4058.
28. Amir AD, Davis KL, Tadmor MD, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol. 2013; 31(6):545-552.
29. Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD81 T cell homeostasis. J Exp Med. 2004; 200(7):825-834.
30. Roychowdhury S, Blaser BW, Freud AG, et al. IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. Blood. 2005;106(7):2433-2435.
31. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011; 365(22):2055-2066.
32. Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115(21):4293-4301.
33. Gleason MK, Lenvik TR, McCullar V, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood. 2012;119(13):3064-3072.
34. Ndhlovu LC, Lopez-Vergès S, Barbour JD, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012;119(16):3734-3743.
35. da Silva IP, Gallois A, Jimenez-Baranda S, et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 2014;2(5):410-422.
36. Berrien-Elliott MM, Romee R, Fehniger TA. Improving natural killer cell cancer immunotherapy. Curr Opin Organ Transplant. 2015; 20(6):671-680.